A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : SGLT2 / sodium-dependent glucose cotransporter 2

[Related PubMed/MEDLINE]
Total Number of Papers: 64
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   SGLT2  (>> Co-occurring Abbreviation)
Long Form:   sodium-dependent glucose cotransporter 2
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2020 Model-based Prediction of the Long-term Glucose-Lowering Effects of Ipragliflozin, a Selective Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor, in Patients with Type 2 Diabetes Mellitus. Emax, FPG, HbA1c, T2DM, UGE
2019 A Fluorescent Glucose Transport Assay for Screening SGLT2 Inhibitors in Endogenous SGLT2-Expressing HK-2 Cells. ---
2019 A novel SGLT2 inhibitor, SU-011, improves glycaemic control in rodents without the risk of hypoglycaemia and weight gain. STZ
2019 Clinical potential of treatment with semaglutide in type 2 diabetes patients. CV, CVD, CVOT, DPP4, FPG, OADs, SmPC
2019 Combination Therapy with Empagliflozin and Insulin Results in Successful Glycemic Control: A Case Report of Uncontrolled Diabetes Caused by Autoimmune Pancreatitis and Subsequent Steroid Treatment. ---
2019 Design, synthesis and biological evaluation of 6-deoxy O-spiroketal C-arylglucosides as novel renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. SAR
2019 Effect of ipragliflozin, an SGLT2 inhibitor, on cardiac histopathological changes in a non-diabetic rat model of cardiomyopathy. HR, LV, SBP
2019 First-dose effect of the SGLT2 inhibitor ipragliflozin on cardiovascular activity in spontaneously diabetic Torii fatty rats. HR, SBP, SD, SDT
2019 Identification of novel small molecule inhibitors for solute carrier SGLT1 using proteochemometric modeling. SGLT1
10  2019 Study on the interaction of ertugliflozin with human serum albumin in vitro by multispectroscopic methods, molecular docking, and molecular dynamics simulation. HSA
11  2019 Study Protocol for the Effects of Formula Diet with Dapagliflozin on Metabolic Improvement and Body Composition in Type 2 Diabetes Mellitus. FD, UMIN
12  2019 Synthesis and biological evaluation of N-glucosyl indole derivatives as sodium-dependent glucose co-transporter 2 inhibitors. ---
13  2019 The management of diabetes mellitus-imperative role of natural products against dipeptidyl peptidase-4, alpha-glucosidase and sodium-dependent glucose co-transporter 2 (SGLT2). SAR
14  2019 Upregulation Of Renal GLUT2 And SGLT2 Is Involved In High-Fat Diet-Induced Gestational Diabetes In Mice. GDM, GLUT2, HFD, IPGTT, T2DM
15  2018 Ertugliflozin as a monotherapy for the treatment of type 2 diabetes. T2DM
16  2018 Identification of an oxime-containing C-glucosylarene as a potential inhibitor of sodium-dependent glucose co-transporter 2. hERG, hSGLT2
17  2018 Plasma Pharmacokinetic Determination of Canagliflozin and Its Metabolites in a Type 2 Diabetic Rat Model by UPLC-MS/MS. ---
18  2018 Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma. LADC, Me4FDG, PET
19  2018 Susceptibility to serious skin and subcutaneous tissue disorders and skin tissue distribution of sodium-dependent glucose co-transporter type 2 (SGLT2) inhibitors. JADER, PMS
20  2017 C-Glycopyranosyl Arenes and Hetarenes: Synthetic Methods and Bioactivity Focused on Antidiabetic Potential. ---
21  2017 Cardioprotective effects of SGLT2 inhibitors are possibly associated with normalization of the circadian rhythm of blood pressure. BP, CV
22  2017 Discovery of a Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor (HSK0935) for the Treatment of Type 2 Diabetes. SD
23  2017 The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes. STZ
24  2016 A validated LC-MS/MS method for the determination of canagliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, in a lower volume of rat plasma: application to pharmacokinetic studies in rats. ---
25  2016 Development and validation of an LC-MS/MS method for the determination of tofogliflozin in plasma and its application to a pharmacokinetic study in rats. LLOQ, SRM
26  2016 Effects of diuretics on sodium-dependent glucose cotransporter 2 inhibitor-induced changes in blood pressure in obese rats suffering from the metabolic syndrome. BP, SHRcp
27  2016 Functional imaging of pharmacological action of SGLT2 inhibitor ipragliflozin via PET imaging using 11C-MDG. 11C-MDG, PET
28  2016 N-Indolylglycosides bearing modifications at the glucose C6-position as sodium-dependent glucose co-transporter 2 inhibitors. SAR
29  2016 [The new ESC Guidelines for acute and chronic heart failure 2016]. CRT, ECG, ESC, HF, HFA, HFpEF, LBBB, LVEF
30  2015 A quantitative LC-MS/MS method for determining ipragliflozin, a sodium-glucose co-transporter 2 (SGLT-2) inhibitor, and its application to a pharmacokinetic study in rats. IS
31  2015 Design of SGLT2 Inhibitors for the Treatment of Type 2 Diabetes: A History Driven by Biology to Chemistry. SAR
32  2015 Development and application of a fluorescent glucose uptake assay for the high-throughput screening of non-glycoside SGLT2 inhibitors. ---
33  2015 Development of sotagliflozin, a dual sodium-dependent glucose transporter 1/2 inhibitor. ---
34  2015 Randomized efficacy and safety trial of once-daily remogliflozin etabonate for the treatment of type 2 diabetes. RE
35  2014 A patient-centered approach to managing patients with type 2 diabetes. ---
36  2014 Analysis of the efficacy of SGLT2 inhibitors using semi-mechanistic model. ---
37  2014 Discovery of 6-deoxydapagliflozin as a highly potent sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. hSGLT2
38  2014 Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects. RE, SE
39  2013 C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors. HF-KK
40  2013 First human dose-escalation study with remogliflozin etabonate, a selective inhibitor of the sodium-glucose transporter 2 (SGLT2), in healthy subjects and in subjects with type 2 diabetes mellitus. PK, RE, T2DM, UGE
41  2013 N-Glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors. hSGLT2, hSGLT2, UGE
42  2013 Safety, pharmacokinetics and pharmacodynamics of remogliflozin etabonate, a novel SGLT2 inhibitor, and metformin when co-administered in subjects with type 2 diabetes mellitus. RE, T2DM, UGE
43  2012 A specific pharmacophore model of sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. ---
44  2012 Early insulin therapy prevents beta cell loss in a mouse model for permanent neonatal diabetes (Munich Ins2(C95S)). BiP, ER, P-eIF2alpha
45  2012 Remogliflozin etabonate, a selective inhibitor of the sodium-dependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. RE, T2DM, UGE
46  2012 Synthesis and biological evaluation of novel C-indolylxylosides as sodium-dependent glucose co-transporter 2 inhibitors. STZ
47  2011 5a-Carba-beta-D-glucopyranose derivatives as novel sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. ---
48  2011 C-aryl glucosides substituted at the 4'-position as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. ---
49  2011 Discovery of novel N-beta-D-xylosylindole derivatives as sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the management of hyperglycemia in diabetes. SD, STZ
50  2011 Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose co-transporter 2, in patients with type 2 diabetes mellitus. T2DM
51  2011 [The kidney: target for blood glucose-lowering therapy]. ---
52  2010 (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. PK, SGLT, SPB
53  2010 Conformationally constrained spiro C-arylglucosides as potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. ---
54  2010 Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus. HF-KK
55  2010 Discovery of non-glycoside sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors by ligand-based virtual screening. ---
56  2010 ortho-Substituted C-aryl glucosides as highly potent and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. ---
57  2010 Renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for new anti-diabetic agent. SARs, SGLTs
58  2010 Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. ---
59  2009 Exploration of O-spiroketal C-arylglucosides as novel and selective renal sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. ---
60  2009 Novel L-xylose derivatives as selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitors for the treatment of type 2 diabetes. ---
61  2009 O-Spiro C-aryl glucosides as novel sodium-dependent glucose co-transporter 2 (SGLT2) inhibitors. ---
62  2008 Aglycone exploration of C-arylglucoside inhibitors of renal sodium-dependent glucose transporter SGLT2. ---
63  2008 Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. STZ
64  2008 Effects of AVE2268, a substituted glycopyranoside, on urinary glucose excretion and blood glucose in mice and rats. UGE